Global Perspectives: Taiwan and Asia (ML Yu and RN Chien, Section Editors)

Current Hepatitis Reports

, Volume 12, Issue 3, pp 157-164

First online:

Tertiary Prevention of HBV-related HCC in Asia

  • Grace Lai-Hung WongAffiliated withInstitute of Digestive Disease, The Chinese University of Hong KongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong
  • , Ching-Ning ChongAffiliated withInstitute of Digestive Disease, The Chinese University of Hong KongDepartment of Surgery, The Chinese University of Hong Kong
  • , Vincent Wai-Sun WongAffiliated withInstitute of Digestive Disease, The Chinese University of Hong KongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Chronic hepatitis B is the leading cause of hepatocellular carcinoma (HCC) in Asia. Despite liver resection or local ablation therapy, up to 70 % of patients will have HCC recurrence. While early HCC recurrence within 2 years of index treatment is mainly associated with tumor characteristics such as vascular invasion and tumor number, late recurrence arises due to field effect and is associated with high hepatitis B virus DNA level and hepatic necroinflammation. Although current data suggest that antiviral therapy can reduce the risk of cirrhosis and incident HCC, its role in preventing HCC recurrence after curative treatment remains controversial. In recent years, knowledge on the signaling pathways of HCC has led to exciting development in targeted therapy, with sorafenib being the first to be registered for the treatment of advanced HCC. Further studies are needed to clarify the role of targeted therapy in the adjuvant setting to prevent HCC recurrence.

Keywords

Hepatitis B HBV DNA Hepatocellular carcinoma Cirrhosis Lamivudine Entecavir Tenofovir Interferon Sorafenib Sirolimus